论文部分内容阅读
目的:了解拉米夫定对失代偿期乙型肝炎肝硬化疗效。方法:将40例乙型肝炎肝硬化失代偿期患者随机分为2组,治疗组20例,对照组20例。2组均采用常规内科综合治疗,治疗组加用拉米夫定100mg/d,口服,疗程48周。结果:治疗组在治疗结束时在小时BVDNA水平、肝功能、血清肝纤维化指标、凝血酶原活动度及Child-Pugh评分等方面与治疗前比较,差异有统计学意义(P<0.05)。结论:拉米夫定抗病毒治疗能明显改善失代偿期肝硬化患者的肝功能及预后。
Objective: To understand the effect of lamivudine on decompensated hepatitis B cirrhosis. Methods: Forty patients with decompensated hepatitis B cirrhosis were randomly divided into two groups: treatment group (20 cases) and control group (20 cases). The two groups were treated with routine medical treatment, the treatment group plus lamivudine 100mg / d, orally, for 48 weeks. Results: There were significant differences in BVDNA, liver function, serum hepatic fibrosis index, prothrombin activity and Child-Pugh score at the end of treatment between the treatment group and before treatment, the difference was statistically significant (P <0.05). Conclusion: Lamivudine antiviral therapy can significantly improve liver function and prognosis in patients with decompensated cirrhosis.